The PAVmed Inc (PAVM) share price is expected to increase by 461.8% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered PAVM. Price targets range from $4 at the low end to $22 at the high end. The current analyst consensus for PAVM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
PAVM is a stock in Health Care which has been forecasted to be worth $10 as an average. On the higher end, the forecast price is $22 USD by from and on the lower end PAVM is forecasted to be $4 by from .
These are the latest 20 analyst ratings of PAVM.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Ross Osborn Cantor Fitzgerald | Neutral | $1.4 | Reiterates | Aug 18, 2023 |
Ross Osborn Cantor Fitzgerald | Neutral | $1.5 | Downgrade | Jan 20, 2023 |
Frank Takkinen Lake Street | Buy | $1.5 | Maintains | Jan 18, 2023 |
Frank Takkinen Lake Street | Buy | $5 | Maintains | Aug 17, 2022 |
Cantor Fitzgerald | Overweight | Initiates | Mar 30, 2021 | |
Ascendiant Capital | Buy | Initiates | Nov 5, 2020 | |
Lake Street | Buy | Initiates | Oct 13, 2020 | |
Maxim Group | Buy | Initiates | Jun 28, 2018 |
When did it IPO
2016
Staff Count
107
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Lishan Aklog M.D.
Market Cap
$9.1M
In 2023, PAVM generated $2.5M in revenue, which was a increase of 550.40% from the previous year. This can be seen as a signal that PAVM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.